168 related articles for article (PubMed ID: 37184294)
21. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.
Young RM; Wu T; Schmitz R; Dawood M; Xiao W; Phelan JD; Xu W; Menard L; Meffre E; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Staudt LM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13447-54. PubMed ID: 26483459
[TBL] [Abstract][Full Text] [Related]
22. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
[TBL] [Abstract][Full Text] [Related]
23. Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL.
Eken JA; Koning MT; Kupcova K; Sepúlveda Yáñez JH; de Groen RAL; Quinten E; Janssen J; van Bergen CAM; Vermaat JSP; Cleven A; Navarrete MA; Ylstra B; de Jong D; Havranek O; Jumaa H; Veelken H
J Exp Med; 2024 May; 221(5):. PubMed ID: 38512136
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
[TBL] [Abstract][Full Text] [Related]
25. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.
Masir N; Akhter A; Roshan TM; Florence CS; Abdul-Rahman F; Tumian NR; Kean-Chang P; Elyamany G; Shabani-Rad MT; Mansoor A
J Clin Pathol; 2019 Sep; 72(9):630-635. PubMed ID: 31189540
[TBL] [Abstract][Full Text] [Related]
26. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
27. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
28. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
29. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
30. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Roschewski M; Patel MR; Reagan PM; Saba NS; Collins GP; Arkenau HT; de Vos S; Nuttall B; Acar M; Burke K; White RD; Udriste M; Sharma S; Dougherty B; Stetson D; Jenkins D; Mortlock A; Forcina A; Munugalavadla V; Flinn I
Clin Cancer Res; 2023 Sep; 29(17):3301-3312. PubMed ID: 37364001
[TBL] [Abstract][Full Text] [Related]
31. Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Kong W; Sender S; Perez SV; Sekora A; Ruetgen B; Junghanss C; Nolte I; Murua Escobar H
Anticancer Res; 2020 Jul; 40(7):3781-3792. PubMed ID: 32620617
[TBL] [Abstract][Full Text] [Related]
32. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
[TBL] [Abstract][Full Text] [Related]
33. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
34. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
Dunleavy K; Erdmann T; Lenz G
Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic Rewiring of BCR Signaling as a Novel Mechanism of Ibrutinib Resistance in ABC-DLBCL.
Pasqualucci L
Blood Cancer Discov; 2021 Nov; 2(6):555-558. PubMed ID: 35015676
[TBL] [Abstract][Full Text] [Related]
36. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
[TBL] [Abstract][Full Text] [Related]
37. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
38. SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.
Wu W; Lu P; Patel P; Ma J; Cai KQ; Mallikarjuna VS; Poureghbali S; Nakhoda SR; Nejati R; Lynn Wang Y
Oncogene; 2023 Feb; 42(6):409-420. PubMed ID: 36482202
[TBL] [Abstract][Full Text] [Related]
39. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
Lam LT; Davis RE; Ngo VN; Lenz G; Wright G; Xu W; Zhao H; Yu X; Dang L; Staudt LM
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20798-803. PubMed ID: 19104039
[TBL] [Abstract][Full Text] [Related]
40. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.
Rink JS; Yang S; Cen O; Taxter T; McMahon KM; Misener S; Behdad A; Longnecker R; Gordon LI; Thaxton CS
Mol Pharm; 2017 Nov; 14(11):4042-4051. PubMed ID: 28933554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
